Ingevity Corporation (NYSE:NGVT - Get Free Report) CEO David Li sold 5,000 shares of the company's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $75.73, for a total transaction of $378,650.00. Following the completion of the sale, the chief executive officer directly owned 125,636 shares of the company's stock, valued at approximately $9,514,414.28. This trade represents a 3.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ingevity Stock Down 2.4%
Ingevity stock traded down $1.78 during midday trading on Tuesday, hitting $74.01. 177,777 shares of the company's stock were exchanged, compared to its average volume of 291,037. The company has a debt-to-equity ratio of 22.52, a quick ratio of 1.15 and a current ratio of 1.61. The company has a market cap of $2.54 billion, a PE ratio of 50.34 and a beta of 1.16. The firm has a 50-day moving average of $73.75 and a two-hundred day moving average of $71.72. Ingevity Corporation has a 12 month low of $45.85 and a 12 month high of $79.29.
Ingevity (NYSE:NGVT - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.33 by $0.41. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. The business had revenue of $314.10 million during the quarter, compared to analyst estimates of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. As a group, analysts expect that Ingevity Corporation will post 5.4 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
NGVT has been the topic of several recent research reports. Wall Street Zen cut Ingevity from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 1st. Weiss Ratings upgraded Ingevity from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $80.00.
Read Our Latest Stock Report on NGVT
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC raised its stake in shares of Ingevity by 10.9% during the 1st quarter. AQR Capital Management LLC now owns 13,410 shares of the company's stock worth $518,000 after acquiring an additional 1,323 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Ingevity by 5.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,790 shares of the company's stock valued at $863,000 after acquiring an additional 1,080 shares in the last quarter. Empowered Funds LLC grew its holdings in Ingevity by 12.9% in the first quarter. Empowered Funds LLC now owns 5,181 shares of the company's stock worth $205,000 after purchasing an additional 594 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Ingevity by 311.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company's stock worth $23,769,000 after purchasing an additional 454,579 shares during the last quarter. Finally, Jane Street Group LLC increased its position in shares of Ingevity by 306.1% during the first quarter. Jane Street Group LLC now owns 88,883 shares of the company's stock worth $3,519,000 after purchasing an additional 66,995 shares in the last quarter. Hedge funds and other institutional investors own 91.59% of the company's stock.
About Ingevity
(
Get Free Report)
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Ingevity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ingevity wasn't on the list.
While Ingevity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
